bio-pharma | Mehl Partners

Gilead Sciences to Acquire Kite Pharma for $11.9B

Gilead Sciences to Acquire Kite Pharma for $11.9B

BIO-PHARMA, BIO-TECH, CALIFORNIA, ISRAEL, M&A, NASDAQ, SANTA MONICA

Photo: Dr. Arie Belldegrun, Founder, Chairman & CEO of Kite Pharma.]]>

Thermo Fisher Scientific to Acquire Patheon in $7.2B Deal

Thermo Fisher Scientific to Acquire Patheon in $7.2B Deal

BIO-PHARMA, BIO-TECH, LIFE SCIENCES, M&A, MASSACHUSETTS, NORTH CAROLINA, NYSE, PHARMACEUTICALS

Perrigo $PRGO to Sell Tysabri Royalty Stream to Royalty Pharma for Up to $2.85B

Perrigo $PRGO to Sell Tysabri Royalty Stream to Royalty Pharma for Up to $2.85B

BIO-PHARMA, INTELLECTUAL PROPERTY, IRELAND, ISRAEL, LIFE SCIENCES, M&A, NEW YORK CITY, NYSE, PATENTS, PHARMACEUTICALS, TEL AVIV STOCK EXCHANGE

Johnson & Johnson to Acquire Swiss Biotech Company Actelion for $30B

Johnson & Johnson to Acquire Swiss Biotech Company Actelion for $30B

BASEL, BIO-PHARMA, BIO-TECH, HEALTHCARE, M&A, NEW JERSEY, NYSE, PHARMACEUTICALS, SIX SWISS EXCHANGE

Lonza to Acquire Capsugel from $KKR for $5.5B

Lonza to Acquire Capsugel from $KKR for $5.5B

BASEL, BIO-PHARMA, M&A, NEW JERSEY, PHARMACEUTICALS, PRIVATE EQUITY, SIX SWISS EXCHANGE

Photo: Capsugel Exhibit at 2014 CPhI Show (Courtesy, That’s Nice)]]>

« Older Entries